One of the most vulnerable groups in global medicine has just gained something it has never had before: a malaria treatment built specifically for them.
On April 24, 2026, the World Health Organization announced the prequalification of the first-ever malaria treatment developed for newborns and young infants weighing between 2 and 5 kilograms. Until now, babies this small were often treated with formulations designed for older children, increasing the risk of dosing errors, side effects, and toxicity.
Why this matters
WHO said the new formulation, artemether-lumefantrine, helps close a long-standing treatment gap affecting some of the youngest patients in malaria-endemic regions. Prequalification means the medicine meets international standards for quality, safety, and efficacy, and it opens the door to broader public-sector procurement.
That matters enormously in Africa, where malaria still claims huge numbers of young lives and where roughly 30 million babies are born every year in malaria-endemic areas.
A bigger wave of progress
The announcement came ahead of World Malaria Day and alongside new WHO-prequalified diagnostic tests designed to catch malaria strains that can evade some older rapid tests. WHO says those advances add to a growing arsenal that now includes vaccines, next-generation mosquito nets, better diagnostics, and more targeted medicines.
In other words, this is not just one new drug. It is another sign that malaria control is still moving forward, even against a disease that has burdened humanity for centuries.
Sources: World Health Organization, Novartis
